Cargando…

A machine learning model for grade 4 lymphopenia prediction during pelvic radiotherapy in patients with cervical cancer

BACKGROUND/PURPOSE: Severe lymphopenia during pelvic radiotherapy (RT) predicts poor survival in patients with cervical cancer. However, the risk of severe lymphopenia has not been well predicted. We developed a machine learning model using clinical and dosimetric information to predict grade 4 (G4)...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Zhiyuan, Yang, Li, Yu, Hao, Guo, Linlang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524190/
https://www.ncbi.nlm.nih.gov/pubmed/36185193
http://dx.doi.org/10.3389/fonc.2022.905222
_version_ 1784800452711284736
author Xu, Zhiyuan
Yang, Li
Yu, Hao
Guo, Linlang
author_facet Xu, Zhiyuan
Yang, Li
Yu, Hao
Guo, Linlang
author_sort Xu, Zhiyuan
collection PubMed
description BACKGROUND/PURPOSE: Severe lymphopenia during pelvic radiotherapy (RT) predicts poor survival in patients with cervical cancer. However, the risk of severe lymphopenia has not been well predicted. We developed a machine learning model using clinical and dosimetric information to predict grade 4 (G4) lymphopenia during pelvic RT in patients with cervical cancer. METHODS: This retrospective study included cervical cancer patients treated with definitive pelvic RT ± induction/concurrent chemotherapy. Clinical information and a set of dosimetric parameters of external beam radiotherapy plan were collected. G4 lymphopenia during RT, which was also referred to as G4 absolute lymphocyte count (ALC) nadir, was defined as ALC nadir <0.2 × 10(9) cells/L during RT according to Common Terminology Criteria for Adverse Events (CTCAE) v4.03. Elastic-net logistic regression models were constructed for the prediction of G4 lymphopenia during pelvic RT using a repeated cross-validation methodology. RESULTS: A total of 130 patients were eligible, and 43 (33.1%) patients had G4 lymphopenia during RT. On multivariable analysis, G4 ALC nadir was associated with poor overall survival (OS) [hazard ratio (HR), 3.91; 95% confidence interval (CI), 1.34–11.38, p = 0.01]. Seven significant factors [Eastern Cooperative Oncology Group (ECOG) performance score, pre-RT hemoglobin, pre-RT lymphocytes, concurrent chemotherapy, gross tumor volume of regional lymphadenopathy (GTV_N volume), body volume, and maximum dose of planning target volume receiving at least 55 Gy (PTV_5500 Dmax)] were obtained by elastic-net logistic regression models and were included in the final prediction model for G4 ALC nadir. The model’s predicting ability in test set was area under the curve (AUC) = 0.77 and accuracy = 0.76. A nomogram of the final predicting model was constructed. CONCLUSIONS: This study developed and validated a comprehensive model integrating clinical and dosimetric parameters by machine learning method, which performed well in predicting G4 lymphopenia during pelvic RT for cervical cancer and will facilitate physicians to identify patients at high risk of G4 lymphopenia who might benefit from modified treatment approaches.
format Online
Article
Text
id pubmed-9524190
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95241902022-10-01 A machine learning model for grade 4 lymphopenia prediction during pelvic radiotherapy in patients with cervical cancer Xu, Zhiyuan Yang, Li Yu, Hao Guo, Linlang Front Oncol Oncology BACKGROUND/PURPOSE: Severe lymphopenia during pelvic radiotherapy (RT) predicts poor survival in patients with cervical cancer. However, the risk of severe lymphopenia has not been well predicted. We developed a machine learning model using clinical and dosimetric information to predict grade 4 (G4) lymphopenia during pelvic RT in patients with cervical cancer. METHODS: This retrospective study included cervical cancer patients treated with definitive pelvic RT ± induction/concurrent chemotherapy. Clinical information and a set of dosimetric parameters of external beam radiotherapy plan were collected. G4 lymphopenia during RT, which was also referred to as G4 absolute lymphocyte count (ALC) nadir, was defined as ALC nadir <0.2 × 10(9) cells/L during RT according to Common Terminology Criteria for Adverse Events (CTCAE) v4.03. Elastic-net logistic regression models were constructed for the prediction of G4 lymphopenia during pelvic RT using a repeated cross-validation methodology. RESULTS: A total of 130 patients were eligible, and 43 (33.1%) patients had G4 lymphopenia during RT. On multivariable analysis, G4 ALC nadir was associated with poor overall survival (OS) [hazard ratio (HR), 3.91; 95% confidence interval (CI), 1.34–11.38, p = 0.01]. Seven significant factors [Eastern Cooperative Oncology Group (ECOG) performance score, pre-RT hemoglobin, pre-RT lymphocytes, concurrent chemotherapy, gross tumor volume of regional lymphadenopathy (GTV_N volume), body volume, and maximum dose of planning target volume receiving at least 55 Gy (PTV_5500 Dmax)] were obtained by elastic-net logistic regression models and were included in the final prediction model for G4 ALC nadir. The model’s predicting ability in test set was area under the curve (AUC) = 0.77 and accuracy = 0.76. A nomogram of the final predicting model was constructed. CONCLUSIONS: This study developed and validated a comprehensive model integrating clinical and dosimetric parameters by machine learning method, which performed well in predicting G4 lymphopenia during pelvic RT for cervical cancer and will facilitate physicians to identify patients at high risk of G4 lymphopenia who might benefit from modified treatment approaches. Frontiers Media S.A. 2022-09-15 /pmc/articles/PMC9524190/ /pubmed/36185193 http://dx.doi.org/10.3389/fonc.2022.905222 Text en Copyright © 2022 Xu, Yang, Yu and Guo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Xu, Zhiyuan
Yang, Li
Yu, Hao
Guo, Linlang
A machine learning model for grade 4 lymphopenia prediction during pelvic radiotherapy in patients with cervical cancer
title A machine learning model for grade 4 lymphopenia prediction during pelvic radiotherapy in patients with cervical cancer
title_full A machine learning model for grade 4 lymphopenia prediction during pelvic radiotherapy in patients with cervical cancer
title_fullStr A machine learning model for grade 4 lymphopenia prediction during pelvic radiotherapy in patients with cervical cancer
title_full_unstemmed A machine learning model for grade 4 lymphopenia prediction during pelvic radiotherapy in patients with cervical cancer
title_short A machine learning model for grade 4 lymphopenia prediction during pelvic radiotherapy in patients with cervical cancer
title_sort machine learning model for grade 4 lymphopenia prediction during pelvic radiotherapy in patients with cervical cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524190/
https://www.ncbi.nlm.nih.gov/pubmed/36185193
http://dx.doi.org/10.3389/fonc.2022.905222
work_keys_str_mv AT xuzhiyuan amachinelearningmodelforgrade4lymphopeniapredictionduringpelvicradiotherapyinpatientswithcervicalcancer
AT yangli amachinelearningmodelforgrade4lymphopeniapredictionduringpelvicradiotherapyinpatientswithcervicalcancer
AT yuhao amachinelearningmodelforgrade4lymphopeniapredictionduringpelvicradiotherapyinpatientswithcervicalcancer
AT guolinlang amachinelearningmodelforgrade4lymphopeniapredictionduringpelvicradiotherapyinpatientswithcervicalcancer
AT xuzhiyuan machinelearningmodelforgrade4lymphopeniapredictionduringpelvicradiotherapyinpatientswithcervicalcancer
AT yangli machinelearningmodelforgrade4lymphopeniapredictionduringpelvicradiotherapyinpatientswithcervicalcancer
AT yuhao machinelearningmodelforgrade4lymphopeniapredictionduringpelvicradiotherapyinpatientswithcervicalcancer
AT guolinlang machinelearningmodelforgrade4lymphopeniapredictionduringpelvicradiotherapyinpatientswithcervicalcancer